Last reviewed · How we verify
Rituxan +CHOP
Rituxan is a monoclonal antibody that targets and depletes CD20-positive B cells, while CHOP is a chemotherapy regimen that includes cyclophosphamide, doxorubicin, vincristine, and prednisone.
Rituxan is a monoclonal antibody that targets and depletes CD20-positive B cells, while CHOP is a chemotherapy regimen that includes cyclophosphamide, doxorubicin, vincristine, and prednisone. Used for Non-Hodgkin's lymphoma, Chronic lymphocytic leukemia.
At a glance
| Generic name | Rituxan +CHOP |
|---|---|
| Sponsor | Shandong New Time Pharmaceutical Co., LTD |
| Drug class | Monoclonal antibody |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Rituxan works by binding to the CD20 antigen on the surface of B cells, marking them for destruction by the immune system. CHOP is a combination of chemotherapy drugs that work by interfering with cell division and DNA replication, ultimately leading to cell death.
Approved indications
- Non-Hodgkin's lymphoma
- Chronic lymphocytic leukemia
Common side effects
- Infusion-related reactions
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL (PHASE2)
- Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (PHASE2, PHASE3)
- Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (PHASE2)
- A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) (PHASE3)
- Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma (PHASE1)
- Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL (PHASE2)
- Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |